Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitors
Plain-language summary
This retrospective cohort study examined whether receiving an influenza vaccine around the time of immune checkpoint inhibitor therapy was associated with the severity of immune-related adverse events in patients with advanced thoracic cancer. Vaccinated patients had less severe immune-related adverse events overall and a lower risk of severe (grade 3-5) events, while vaccination showed no association with survival times. The authors conclude that influenza vaccination did not increase treatment toxicity in these patients and was linked to a reduced risk of severe immune-related events.
Read the full paper (DOI: 10.1183/23120541.00684-2021).
This is a plain-language summary written for discoverability; the authoritative version is the published paper. Part of Travis Osterman's peer-reviewed publications.